India has granted market authorisation to Takeda Biopharmaceuticals’ dengue vaccine QDENGA, making it the country’s first approved vaccine for dengue prevention. The approval by CDSCO follows extensive global and Indian clinical trials confirming its safety and efficacy.
India has approved its first dengue vaccine, QDENGA, for individuals aged 4 to 60 years. The DCGI clearance allows vaccination without pre-screening and marks a major step in strengthening dengue prevention alongside surveillance, vector control and public health measures.
